{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:20:18Z","timestamp":1792808418776,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Evelo Biosciences, Inc., Cambridge, MA, USA and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD)."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10637-025-01573-0","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T23:42:13Z","timestamp":1755646933000},"page":"894-903","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Phase 1\/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor\u2013relapsed tumors"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4789-4913","authenticated-orcid":false,"given":"Judy S.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward R.","family":"Arrowsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Thaddeus","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Friedmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahima","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"McHale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humphrey","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Chisamore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna V.","family":"Ulahannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"1573_CR1","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C et al (2023) Immune checkpoint therapy-current perspectives and future directions. Cell 186:1652\u20131669. https:\/\/doi.org\/10.1016\/j.cell.2023.03.006","journal-title":"Cell"},{"key":"1573_CR2","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/2326-6066.Cir-20-0586","volume":"10","author":"M Karasarides","year":"2022","unstructured":"Karasarides M, Cogdill AP, Robbins PB, Bowden M, Burton EM, Butterfield LH, Cesano A, Hammer C, Haymaker CL et al (2022) Hallmarks of resistance to immune-checkpoint inhibitors. Cancer Immunol Res 10:372\u2013383. https:\/\/doi.org\/10.1158\/2326-6066.Cir-20-0586","journal-title":"Cancer Immunol Res"},{"key":"1573_CR3","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41422-020-0332-7","volume":"30","author":"D Zheng","year":"2020","unstructured":"Zheng D, Liwinski T, Elinav E (2020) Interaction between microbiota and immunity in health and disease. Cell Res 30:492\u2013506. https:\/\/doi.org\/10.1038\/s41422-020-0332-7","journal-title":"Cell Res"},{"key":"1573_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1126\/science.aar2946","volume":"359","author":"C Jobin","year":"2018","unstructured":"Jobin C (2018) Precision medicine using microbiota. Science 359:32\u201334. https:\/\/doi.org\/10.1126\/science.aar2946","journal-title":"Science"},{"key":"1573_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, Fluckiger A, Messaoudene M, Rauber C et al (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359:91\u201397. https:\/\/doi.org\/10.1126\/science.aan3706","journal-title":"Science"},{"key":"1573_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF (2018) The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359:104\u2013108. https:\/\/doi.org\/10.1126\/science.aao3290","journal-title":"Science"},{"key":"1573_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359:97\u2013103. https:\/\/doi.org\/10.1126\/science.aan4236","journal-title":"Science"},{"key":"1573_CR8","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M Vetizou","year":"2015","unstructured":"Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP et al (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350:1079\u20131084. https:\/\/doi.org\/10.1126\/science.aad1329","journal-title":"Science"},{"key":"1573_CR9","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1126\/science.aad7706","volume":"350","author":"A Snyder","year":"2015","unstructured":"Snyder A, Pamer E, Wolchok J (2015) Could microbial therapy boost cancer immunotherapy? Science 350:1031\u20131032. https:\/\/doi.org\/10.1126\/science.aad7706","journal-title":"Science"},{"key":"1573_CR10","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","volume":"350","author":"A Sivan","year":"2015","unstructured":"Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B et al (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350:1084\u20131089. https:\/\/doi.org\/10.1126\/science.aac4255","journal-title":"Science"},{"key":"1573_CR11","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41591-022-01694-6","volume":"28","author":"N Dizman","year":"2022","unstructured":"Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, Frankel P, Cui Y, Mira V et al (2022) Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med 28:704\u2013712. https:\/\/doi.org\/10.1038\/s41591-022-01694-6","journal-title":"Nat Med"},{"key":"1573_CR12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41598-018-36926-8","volume":"9","author":"DL Laute-Caly","year":"2019","unstructured":"Laute-Caly DL, Raftis EJ, Cowie P, Hennessy E, Holt A, Panzica DA, Sparre C, Minter B, Stroobach E, Mulder IE (2019) The flagellin of candidate live biotherapeutic Enterococcus gallinarum MRx0518 is a potent immunostimulant. Sci Rep 9:801. https:\/\/doi.org\/10.1038\/s41598-018-36926-8","journal-title":"Sci Rep"},{"key":"1573_CR13","doi-asserted-by":"publisher","first-page":"A283","DOI":"10.1136\/jitc-2020-SITC2020.0283","volume":"8","author":"S Pant","year":"2020","unstructured":"Pant S, Shah A, Msaouel P, Campbell M, Tu S-M, Gao J, Blumenschein G, Mott F, Le X et al (2020) Safety and efficacy signals in the complete phase I study of live biotherapeutic MRX0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIS) [abstract 283]. J Immunother Cancer 8:A283. https:\/\/doi.org\/10.1136\/jitc-2020-SITC2020.0283","journal-title":"J Immunother Cancer"},{"key":"1573_CR14","unstructured":"Francisco-Anderson L, Shariffudin S, Gardner H, Goldberg M, Kashyap S, Abdou M, Davitt C, Argueta S, Parameswaran P et al (2020) A phase I\/II clinical trial of EDP1503 with pembrolizumab for triple-negative breast cancer. Paper presented at: San Antonio Breast Cancer Symposium, San Antonio, TX, USA."},{"key":"1573_CR15","unstructured":"Francisco-Anderson L, Shariffudin S, Gardner H, Goldberg M, Kashyap S, Abdou M, Davitt C, Argueta S, Parameswaran P et al (2020) EDP1503 induces anti-tumor responses via gut-mediated activation of both innate and adaptive immunity. Paper presented at: ESMO World Congress on Gastrointestinal Cancer, Virtual."},{"key":"1573_CR16","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litiere S, Dancey J et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:e143\u2013e152. https:\/\/doi.org\/10.1016\/S1470-2045(17)30074-8","journal-title":"Lancet Oncol"},{"key":"1573_CR17","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/jci91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP et al (2017) IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127:2930\u20132940. https:\/\/doi.org\/10.1172\/jci91190","journal-title":"J Clin Invest"},{"key":"1573_CR18","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.2147\/CMAR.S151023","volume":"11","author":"P du Rusquec","year":"2019","unstructured":"du Rusquec P, de Calbiac O, Robert M, Campone M, Frenel JS (2019) Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data. Cancer Manag Res 11:4297\u20134312. https:\/\/doi.org\/10.2147\/CMAR.S151023","journal-title":"Cancer Manag Res"},{"key":"1573_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im S-A, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J et al (2022) Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med 387:217\u2013226. https:\/\/doi.org\/10.1056\/NEJMoa2202809","journal-title":"N Engl J Med"},{"key":"1573_CR20","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.7150\/ijbs.82776","volume":"19","author":"H Hu","year":"2023","unstructured":"Hu H, Wang K, Jia R, Zeng ZX, Zhu M, Deng YL, Xiong ZJ, Tang JN, Xie H et al (2023) Current status in rechallenge of immunotherapy. Int J Biol Sci 19:2428\u20132442. https:\/\/doi.org\/10.7150\/ijbs.82776","journal-title":"Int J Biol Sci"},{"key":"1573_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_349811","volume":"42","author":"IH Sahin","year":"2022","unstructured":"Sahin IH, Ciombor KK, Diaz LA, Yu J, Kim R (2022) Immunotherapy for microsatellite stable colorectal cancers: challenges and novel therapeutic avenues. Am Soc Clin Oncol Educ Book 42:1\u201312. https:\/\/doi.org\/10.1200\/EDBK_349811","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1573_CR22","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M et al (2019) Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol 30:397\u2013404. https:\/\/doi.org\/10.1093\/annonc\/mdy517","journal-title":"Ann Oncol"},{"key":"1573_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/cancers13010020","volume":"13","author":"K \u015ali\u017cewska","year":"2020","unstructured":"\u015ali\u017cewska K, Markowiak-Kope\u0107 P, \u015ali\u017cewska W (2020) The role of probiotics in cancer prevention. Cancers (Basel) 13:20. https:\/\/doi.org\/10.3390\/cancers13010020","journal-title":"Cancers (Basel)"},{"key":"1573_CR24","doi-asserted-by":"publisher","first-page":"LBA104","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA104","volume":"41","author":"H Ebrahimi","year":"2023","unstructured":"Ebrahimi H, Meza LA, Lee K, Malhotra J, Alcantara M, Zengin ZB, Dizman N, Govindarajan A, Hsu J et al (2023) Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): a randomized clinical trial. J Clin Oncol 41:LBA104. https:\/\/doi.org\/10.1200\/JCO.2023.41.17_suppl.LBA104","journal-title":"J Clin Oncol"},{"key":"1573_CR25","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s11864-022-01027-2","volume":"23","author":"J Zhang","year":"2022","unstructured":"Zhang J, Wu K, Shi C, Li G (2022) Cancer immunotherapy: fecal microbiota transplantation brings light. Curr Treat Options Oncol 23:1777\u20131792. https:\/\/doi.org\/10.1007\/s11864-022-01027-2","journal-title":"Curr Treat Options Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01573-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01573-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01573-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:03:47Z","timestamp":1760195027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01573-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1573"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01573-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol and its amendments were approved by the appropriate local or national ethics committee or institutional review board for each participating center. All participants provided written informed consent. The study was conducted in accordance with the Good Clinical Practice requirements and the ethical principles described in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Judy S Wang: has served in a consulting role for Fusion Pharma; has\u00a0received research funding to the institution from AbbVie, Accutar Biotech, Adagene, Agenus, Allorion Therapeutics, Alterome Therapeutics, Apollo, Artios, Astellas Pharma, Bayer, Beigene, Bicycle Therapeutics, BioNTech SE, Biostar, BioTheryX, Blueprint Medicines, BMS GmbH & Co. KG, Boehringer Ingelheim, C4 Therapeutics, Celgene\/Bristol Myers Squibb, Centessa Pharmaceuticals, Circle Pharma,\u00a0Compass Therapeutics, Compugen, Cullinan Oncology, Conjupro Biotherapeutics, Cyteir, D3 Bio, Daiichi Sankyo\/UCB Japan, DualityBio, Edgewood Oncology, Ellipses Pharma, Erasca Inc, Forty Seven, Genentech\/Roche, GenMab, Georgiamune, GlaxoSmithKline, Hotspot Therapeutics, IgM Biosciences, Immunitas, Immunogen, Immuno-Onc, Janssen, Jazz Pharmaceuticals, Kineta, Klus Pharma, Kumquat, Kura Oncology, Kymab, Loxo\/Lilly, LSK Global, MabSpace Biosciences, Macrogenics, MBQ Pharma, Medikine, MediLink Therapeutics, Menarini,\u00a0Merck KGaA, Mersana, Moderna Therapeutics, NGM Biopharmaceuticals, Novartis, Nurix, Olema Oncology, OnCusp Therapeutics, Pfizer, Phoenix Molecular Designs, Prelude Therapeutics, PureTech, Pyxis, Qilu Puget Sound Biotherapeutics, Quanta Therapeutics, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals, Step Pharma, Syndax, Tango Therapeutics, TeneoBio, Treadwell Therapeutics, Vividion Therapeutics, Xencor, Zai Lab, and\u00a0Zymeworks; and\u00a0has received travel, accommodations, and expenses support from NGM Biopharmaceuticals. Edward R Arrowsmith: has received research funding to the institution from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Calistoga Pharmaceuticals, Celgene, Cephalon, Chorus, Eisai, EMD Serono, Evelo Biosciences, Exelixis, Genentech, Gilead Sciences, Incyte, Merck KGaA, Millennium, Modra, Novartis, Oncogenex, Onyx, Peloton Therapeutics, Pfizer, Sarah Cannon Research Institute, Takeda, Clovis Oncology, Lilly, Infinity Pharmaceuticals, Janssen Research & Development, Leap Therapeutics, F. Hoffmann LaRoche, Loxo, Tolmar, Dana-Farber Cancer Institute, AbbVie, and G1 Therapeutics. J Thaddeus Beck: has received research funding to the institution from Merck & Co., Inc., Rahway, NJ, USA, Bristol Myers Squibb, Lilly, DSI, Novartis, Gilead, AbbVie, Stemline, Arvenist, Pfizer, Johnson and Johnson, and AstraZeneca. Jennifer Friedmann: nothing to disclose. Rahima Jamal: has received honoraria from Pfizer, BMS GmbH & Co. KG, Merck KGaA, and Novartis; has served in a consulting or advisory role for Bristol Myers Squibb, Medison Pharma, Pfizer, Merck KGaA, and Novartis; and has received research funding to the institution from MSD, Bristol Myers Squibb, Iovance Biotherapeutics, Pfizer, BioNTech SE, Astellas Pharma, Pacylex, Novartis, VelsoBio\/Merck, Alkermes, Surface Oncology, Boerhinger Ingelheim, Immunocore, Evelo Biosciences, AstraZeneca\/MedImmune, Roche\/Genentech, and Takeda. Duncan McHale: former employee of Evelo Biosciences, Cambridge, MA, USA. Humphrey Gardner: nothing to disclose. Michael J Chisamore: employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, who may own stock and\/or hold stock options in Merck & Co., Inc., Rahway, NJ, USA. Susanna V Ulahannan: has served on an advisory board for Eisai, AstraZeneca, and IGM Biosciences; and has received research funding to the institution from AbbVie, Inc, Adlai Nortye, Artios Pharma, ArQule, Inc, AstraZeneca, Atreca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Ciclomed LLC, Eisai, Erasca, Evelo Biosciences, Inc, Exelexis, Exthera, G1 Therapeutics, Inc, GSK, IGM Biosciences, Immunitas Therapeutics, Incyte, Isofol, Jazz Pharmaceuticals, Klus Pharma, Inc, Macrogenics, Merck & Co., Inc., Rahway, NJ, USA, Mersana Therapeutics, Omega Therapeutics, OncoMed Pharmaceuticals, Inc, Pfizer, Purple Biotech, Qurgen, Regeneron Pharmaceuticals, Inc, Revolution Medicines, Inc, Sapience Therapeutics,\u00a0Inc, Synermore Biologics Co, Takeda, Tarveda Therapeutics, Tesaro, Tempest Therapeutics, Theradex, Totos Medicines, Inc, Tvardi Therapeutics, and Vigeo Therapeutics Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}